The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) increased its increase by more than 41%. As of press release, it had risen 35.23% to HK$17.62, with a turnover of HK$296 million.

According to the news, on September 18, the company made a big success: Yingpai Pharmaceutical and global pharmaceutical company Pharmanovia jointly announced that the European Medicines Agency (EMA) Commission for Human Medicines (CHMP) has passed a positive opinion recommending approval (MA) for Sepalna® (Senapali), which is intended for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. After approval of the CHMP proposal, Senapali will be submitted to the European Commission for a final decision. Once approved by the European Commission, Senapali will be approved for sale in all EU member states and European Economic Area countries.

In addition, Yingpai Pharmaceutical was recently included in the Hong Kong Stock Exchange list. Southbound capital can be directly traded, and market attention continues to increase. According to market analysts, emotional recovery in the innovative drug sector is compounded by the implementation of the international milestone of the approval of Senapali by the European Medicines Agency, compounding multiple benefits such as the inclusion of Hong Kong Stock Connect and the release of domestic products, driving active capital allocation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.